Novavax Inc. Stock Rises Friday, Outperforms Market

Spectrum Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

SPPI Spectrum Pharmaceuticals Inc

FDBC Fidelity D&D Bancorp Inc

$BUKCHET Bloomberg Coffee Subindex Euro

BMY Bristol-Myers Squibb Co

MLGO MicroAlgo Inc

FRST Primis Financial Corp

VII 7GC & Holdings Co Inc

PEBO Peoples Bancorp Inc

BIOAF Bioasis Technologies Inc

NRGOF Newrange Gold Corp

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Novavax Inc. Stock Rises Friday, Outperforms Market

5:13 pm ET November 11, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) jumped 13.10% to $25.04 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.88% to 11,323.33 and the Dow Jones Industrial Average rising 0.10% to 33,747.86. This was the stock's second consecutive day of gains. Novavax Inc. closed $211.46 below its 52-week high ($236.50), which the company achieved on December 20th.

The stock outperformed some of its competitors Friday, as Replimune Group Inc. (REPL) rose 4.43% to $21.00, VBI Vaccines Inc. (VBIV) rose 0.56% to $0.60, and AnaptysBio Inc. (ANAB) rose 1.54% to $30.97. Trading volume (5.7 M) eclipsed its 50-day average volume of 5.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 11, 2022.

(END) Dow Jones Newswires

November 11, 2022 17:13 ET (22:13 GMT)